Skip to main content

Exciting stuff....exciting year

     I am once again blown away by my current eighth graders and their voracious appetite for writing (and reading!). We started working on WV Promising Young WritersWVDE yesterday and they are SO excited, which makes me equally pumped. After talking about effective "grabbers" and doing a writing sprint on one of seven fictional narrative writing prompts, I know as a certainty that only good things are going to happen in room 208 today. The most memorable "grabber" from yesterday is "It's not safe here anymore". I mean, how does that NOT grab your attention. Good job, G. Baker! I cannot wait to see what is in store for us today.
     On a more personal note: I will be at Barnes and Noble in Morgantown on Saturday, January 19, at 1:00, signing copies of Abby and Raspberry Beret. Since that week is Educator's Week I hope to see many fellow educators/YA readers. I cannot wait to release the third and final installment in my trilogy, but I have set a goal for myself to share my first two novels with as many folks as possible before embarking on a thrid publication process. (Yes, folks, I need to replenish the Lisa Dream Fund before spending more nonexistent money:). So, help me reach my sales goal so I can let you know "happens next".
     Have a good one!

Comments

Popular posts from this blog

Alien feet?

Okay, so after my initial reunion with social media, I naively imagined today to be more productive. But, no...

For someone who doesn't spend much time perusing sites like Pinterest, my interest has suddenly piqued to the point that addiction be a possibility.

Hoping to find someone of like mind, I instead downloaded a slipper pattern I might knit for Christmas presents (oops, there goes the surprise). It looks fairly simple. Let me know if you give it a try.
https://www.pinterest.com/pin/538250592959842993/

And, then, I found this really neat yoga flow outlined for me.
Since yoga seems to be the go-to exercise for us Warriors, I decided to share. That way we do not have to invent our own personalized routine. You're welcome.




Then, I discovered an entire page of memes that put MS in perspective to the causal reader-reluctant  on-looker. And because  this figure is essentially in the child pose... well, you get the picture.

Of course, any information on foot drop always attracts my at…

You are invited to Letters to the MonSter

https://www.youtube.com/watch?v=serV18MirGg

Well, the sun is shining at last and it appears that spring is sincerely here and hinting at summer weather.    That means I need a summer project; hopefully one that I can complete. With two young adult books   in various levels of completion, you will surely tells me how ridiculous I am to start yet another writing project. but, inspiration has no rules, right?
           The entire month of March MS Awareness Month led to so many
awesomeavenues of expressions, fueling my need to share and learn with 
fellow MS Warriors. So, let's hare. Let's learn. In Letters to the MonSter, 
my goal is to allow fellow Warriors to vent, scream, rant, and exorcise the  MonSter out of our lives. Let's unite in this project to erase multiple sclerosis from our lives. As Leslie Hillburn stated in the preface to my last tome to this disease, "...the ONLY place you will get any support and understanding in dealing with me (MS) is with Other People wi…

MS and children

FDA Approves First Treatment for Pediatric MS On May 11, 2018, Novartis announced that Gilenya® (fingolimod) was approved by the United States Food and Drug Administration (FDA) for the treatment of children and adolescents, ages 10 through 17, with relapsing multiple sclerosis (MS). This is the first disease-modifying therapy (DMT) to be approved for this form of the disease in this age group. Known as “pediatric MS,” nearly all of those diagnosed have the relapsing form of the disease. Children also experience approximately two-to-three times as many relapses as an individual with adult-onset MS. A clinical trial comparing Gilenya to Avonex® (interferon beta-1a) in children and adolescents found that those treated with Gilenya saw an 82-percent reduction in their annualized relapse rate over a period of up to two years. Please see MSAA's online news article, "FDA Approves Gilenya® for Pediatric MS,"for more information. If links are disabled in this email, please copy a…